Commonly found with a TMPRSS2:ERG fusion, the concurrent loss of PTEN contributes to a poor prognosis in cancer in the presence of an existing TMPRSS2:ERG fusion [15] with an increased risk of recurrence [16]. The gene discussed is ERG; the disease is cancer.